GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Indraprastha Medical Corporation INDRAMEDCO.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

331.50

+0.39%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Indraprastha Medical Corporation

Its shares trade on NSE under the ticker INDRAMEDCO.NS. It has been listed since 24 February 1997. In the fiscal year to 31 March 2025, it reported revenue of ₹13.56bn and net income of ₹1.61bn. At that date it held total assets of ₹8.52bn and shareholders' equity of ₹5.97bn.

Indraprastha Medical Corp. Ltd. engages in the healthcare business. The company is headquartered in New Delhi, Delhi. The business activities of the Company are running and operating hospitals, which include Indraprastha Apollo Hospitals and Apollo Hospitals. The firm provides various services, such as in-patients, out-patients and clinical services. Indraprastha Apollo Hospitals is a multi-specialty tertiary acute care hospital with approximately 710 beds and is spread over 15 acres and has a built-up area of over 600,000 square feet. Indraprastha Apollo Hospitals has various specialties, such as anesthesia, cardiology, cardiac surgery, cancer, pediatrics, critical care, emergency care, fetal medicine, gastroenterology and hepatology, obstetrics and gynecology, interventional radiology, IVF, liver and kidney transplant, nuclear medicine, nephrology, ophthalmology, plastic and reconstructive surgery, respiratory and sleep medicine, rheumatology, spine surgery, urology and andrology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
24 Feb 1997
Employees
2,947

Leadership

Pay as last reported

  • Mr. Jasmine ShahNon-Executive Chairman of the Board₹650,000
  • Dr. Prathap ReddyNon-Executive Vice Chairman of the Board₹650,000
  • Mr. C. TyagiChief Financial Officer
  • Mr. Priya RanjanCompliance Officer, Company Secretary
  • Mr. P. ShivakumarManaging Director, Executive Director, since 2019₹26.1m
  • Mr. Vikram BhatNon-Executive Director₹1.1m
  • Mr. Udit RaiNon-Executive Director₹850,000
  • Ms. Sangita ReddyNon-Executive Director₹900,000
  • Ms. Suneeta ReddyNon-Executive Director₹1.0m
  • Prof. Dr. Mahesh VermaNon-Executive Director₹850,000
  • Mr. Vinayak ChatterjeeNon-Executive Independent Director₹1.1m
  • Mr. Tejpreet ChopraNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Indraprastha Apollo Hospitals operates 710 beds across 15 acres in New Delhi.
  • Indraprastha Medical Corporation employs 2,947 full-time healthcare professionals.
  • The company offers 20+ medical specialties including cardiac surgery and organ transplants.

Weaknesses

  • Indraprastha Medical Corporation has no international hospital locations beyond New Delhi.
  • The company's business is limited to healthcare services without diversification into other sectors.
  • Apollo Hospitals is the only major hospital brand under the company name.

Opportunities

  • Expanding into tier-2 Indian cities with growing healthcare demand.
  • Increasing telemedicine services to reach rural patients in India.
  • Partnering with insurance providers for broader patient coverage.

Threats

  • Rising operational costs in New Delhi's healthcare market.
  • Competition from other hospital chains in Delhi region.
  • Regulatory changes affecting healthcare pricing in India.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.